NMN and arterial stiffness: what the randomized trial found

The overall vascular comparison was not significant

The 2023 randomized NMN trial did not establish an overall reduction in arterial stiffness compared with placebo. It found a favorable numerical direction and some subgroup signals. That is a reasonable basis for further study, but it is not evidence that an NMN supplement prevents heart attacks or reverses the age of a reader’s blood vessels. ^[1]

This distinction matters because an exploratory result is easy to turn into a shopping claim. A sales page can describe the direction of the average while leaving out whether the treatment and placebo groups differed convincingly. Read the comparison first. The mechanism and the percentage become useful only after the outcome is defined.

A modest amount in middle-aged volunteers

The study randomized 36 healthy adults aged 40–59 to NMN or placebo for twelve weeks. The active protocol supplied 125 mg twice daily, totaling 250 mg per day; one participant in each group did not complete follow-up. Brachial-ankle pulse wave velocity was used as an arterial-stiffness measure. ^[1]

This was neither a long-term cardiovascular-outcome trial nor a head-to-head comparison of retail delivery systems. A study amount is a description of the experiment, not an instruction for a reader. Doubling the amount or changing to a liposomal formulation creates a different intervention; the published result cannot tell us whether that change improves the effect, leaves it unchanged or introduces another problem.

The blood result was more specific than NAD rose

The authors reported higher serum nicotinamide after NMN. Serum NAD+ and NMN were detectable but below the assay’s lower quantification limits, making comparison difficult. ^[1] The practical reading is that the investigators observed an NAD-related metabolic response, rather than a clearly quantified increase in every molecule named in the pathway.

That is an important distinction when comparing marketing graphics. A measured downstream metabolite, a whole-blood NAD+ result and a direct tissue measurement are not interchangeable endpoints. One should not be silently relabeled as another to make different studies appear comparable. If a seller gives a single NAD percentage, ask which specimen and molecule produced it before considering what the percentage might mean.

For the measurement question behind this distinction, read NAD+ biomarkers and meaningful benefit.

A subgroup can generate a better question

The paper reported favorable pulse-wave-velocity findings in participants with above-average body mass index or blood glucose, although its overall group comparison was not significant. ^[1] Those categories came from this study population. Above average within a small healthy cohort does not necessarily describe a patient with obesity, diabetes or established vascular disease.

Our inference is that the subgroup results are most useful for planning a targeted trial. They should not be used to identify a self-selected group of shoppers already proven to benefit. Examining several subsets creates more opportunities to find an interesting pattern. A new study can test whether the pattern persists when the group and outcome are specified in advance.

Related NR evidence is a comparison of questions

A 2018 NR crossover trial included 24 healthy middle-aged and older adults who completed two six-week periods. It demonstrated an NAD-related response and described exploratory blood-pressure and stiffness findings as hypotheses for larger trials. It used NR rather than NMN. ^[2]

The two reports can be discussed together because both explore NAD precursors and vascular measurements. They cannot be pooled informally into proof that every precursor improves cardiovascular health. The molecules, designs and measurements are not identical. Repeatedly seeing a promising direction may strengthen the case for investigation; it does not allow a reviewer to skip the trial that would actually resolve the consumer question.

Vascular age is a translation, not time travel

The NMN investigators also discussed an estimated blood-vessel age derived from pulse-wave measurements. ^[1] Such a calculation translates a measurement through an equation. It is not an observation that someone became biologically younger by the same number of years, and it is not a demonstration of longer life.

A useful reading exercise is to replace the label with the underlying result. Instead of asking how many years were reversed, ask which stiffness measurement changed, what happened in the comparison group and whether the difference was statistically and clinically persuasive. That exercise preserves the interesting biology while preventing a derived number from sounding more concrete than the experiment beneath it.

Twelve weeks does not answer prevention

The NMN report described the tested regimen as well tolerated over twelve weeks. ^[1] That observation belongs beside its limited duration and small sample. It cannot quantify uncommon harms, years of exposure or the effect of combining the product with several other supplements.

An earlier single-arm study in ten healthy men examined single oral NMN administrations of 100, 250 and 500 mg, observing clinical parameters over five hours. It reported no significant clinical symptoms. ^[3] That is useful early tolerability information, but its short observation window cannot answer whether repeated use prevents cardiovascular events or remains suitable over years.

Likewise, a vascular surrogate and a prevented clinical event belong in separate columns. A trial intended to demonstrate prevention would need enough relevant events and follow-up to make that comparison credible. Our assessment is that this study is better used to understand the research pipeline than to justify replacing an established cardiovascular plan with a supplement subscription.

What to compare before paying

For an NMN product, review the actual ingredient, serving amount, testing information and renewal commitment. Those details determine what is being purchased. None turns this small trial into a product-specific demonstration of vascular protection. A lower monthly equivalent may buy more capsules without buying a more certain clinical result.

Keep the conclusion proportionate: NMN has been investigated in a controlled human vascular study, and the overall stiffness result remained uncertain. The narrower subgroup patterns deserve confirmation. A purchasing decision can acknowledge that uncertainty without pretending the research is empty or that the missing cardiovascular outcome has already been supplied by an attractive biological explanation.

For a separate assessment of purchasing terms, see our Renue By Science review; the service review does not establish a treatment benefit.